Integri AI
AI Agents Playground Voice AI PDF Chat Image Generation AI News Blog Pricing Help Contact Log In Sign Up Free

US FDA Rejects Cell Therapy 'Deramiocel' for Duchenne Muscular Dystrophy for a Second Time

Published 2026-11-21

US FDA Rejects Cell Therapy 'Deramiocel' for Duchenne Muscular Dystrophy for a Second Time | Integri News

The US Food and Drug Administration (FDA) has once again refused to approve 'Deramiocel', a cell therapy for treating Duchenne muscular dystrophy. This is the second rejection. The medicine was developed for patients with Duchenne muscular dystrophy, a rare genetic disease that makes the muscles gradually weaker.

Duchenne muscular dystrophy is caused by a lack of dystrophin, a protein that helps build muscle. It mainly affects boys. Over time, walking becomes difficult, and problems with breathing can also develop. At present, there is no treatment that can fully cure this disease. For this reason, many patients and families are waiting for new treatments to become available soon.

Deramiocel is a cell therapy that uses the patient's own heart stem cells. The FDA decided that there was not enough data to confirm the medicine's effectiveness and safety, so it refused approval. The company is reported to be looking for ways to submit additional data and go through the review process again.

This decision shows how important it is to prove safety and effectiveness in developing treatments for rare diseases. For patients, the news means that a new treatment option is delayed. However, experts say that strict reviews are necessary to protect patients. In the future, attention is expected to focus on the results of the FDA's further review and the company's next steps.

Sources: 헬스코리아뉴스

More South Korea news

  • Korean Stock Market on November 20: What Were the Top 50 Gainers?
  • AI and Digital Technology Are Changing Daily Life: 2026 Government Innovation Expo Opens at KINTEX on the 25th
  • President Trump Regrets That Immigration Crackdown Was Too Harsh, but Tightens Rules Further
  • US Air Taxi Company Joby Sees Revenue Rise in Third Quarter
  • K-EnterTech Hub Releases Free Preview Guide for CES 2027
  • Democrats Take Control of Both Houses in U.S. Midterm Elections
  • What Should We Learn from North Korea Diplomacy?
  • Domestic Investors Call for Better Overseas Stock Capital Gains Tax as Tesla and SpaceX Merger Possibility Emerges

All South Korea news · News by country

Home Agents Pricing Blog News Help Privacy Policy Contact Login Sign Up